Redcare Phamacy Unsp/Adr (SAEYY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And gentlemen, welcome to the Red Care Q1 2025 earnings release analyst and investor call. I'm Moritz, the call's call operator. I would like to remind you that all participants will be in a listen-only mode and the conference has been recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. Your presenters today are CEO Olaf Heinrich and CFO Jasper Enhorst. At this time, it's a pleasure to hand over to Monika Ambrosi. Please go ahead. Good morning. This is just a reminder that if you should have an issue accessing the webcast, you should please go to our website to find the link under the events and publications page and the webcast recording. Thank you. Over to Olaf. Yes, thank you very much, Monika, and hello to everybody. Very warm welcome from my side. Sorry if there are any inconvenience with the technology, but I think especially with this hint from Monika that it should work out for all of you. So again, very sorry for that. Let's have a look into the agenda of today. So first, we would like to talk about financial performance, then about a general update, and then by the end of the presentation briefly touch on outlook and guidance 2025. So let's start with the financial performance first. We had a successful start with continued fast growth into 2025. Group sales are up 28% and it's fully organic and driven by ERX reaching 717 million in Q1 of this year. If we look into the different categories, Non-Rx, strong growth at 20%. And if we look into the Rx, Rx in Germany increased 191% compared to last year. But even quarter over quarter, we se...